Surgepays announced its Q4 2023 financial results on March 12, 2024. The company reported an EPS of $0.19, which fell short of the analyst consensus estimate of $0.41 by 53.66%. Quarterly sales were $32.318 million, missing the estimated $33.521 million by 3.59%. This marks a 10.79% decrease from sales of $36.226 million in the same period last year.
The latest earnings report from Surgepays highlights a challenging quarter for the company, with significant deviations from market expectations in both earnings and sales performance.
March 12, 2024: SURG Stock Soars 10.95% Amidst Stable Performance
On March 12, 2024, SURG stock had a strong performance, with the price of shares increasing by $0.69, or 10.95%, since the market last closed. The stock closed at $6.99, trading in the middle of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been relatively stable and is showing positive momentum.
March 12, 2024: SURG Stock Shows Promising Financial Results with Significant Increase in Revenue and Net Income
On March 12, 2024, SURG stock showed promising performances as the company reported strong financial results. According to data from CNN Money, SURG’s total revenue for the past year was $121.54 million, which represented a significant increase of 138.04% compared to the previous year. However, total revenue for the third quarter of the fiscal year was reported at $34.16 million, showing a slight decrease of 4.81% compared to the previous quarter.
Despite the slight decrease in total revenue for the quarter, SURG managed to increase its net income to $7.08 million for Q3, which was a significant improvement of 18.74% compared to the previous quarter. The company also reported a net income of -$680.76K for the past year, showing a notable increase of 94.97% compared to the previous year.
Furthermore, SURG reported an increase in earnings per share (EPS) for both the past year and the third quarter of the fiscal year. The EPS for the past year was -$0.05, which increased by 98.22% compared to the previous year. The EPS for Q3 was $0.49, showing a notable increase of 23.4% compared to the previous quarter.
Overall, SURG’s financial performance on March 12, 2024, reflected a positive trend with significant improvements in net income and EPS. Investors and analysts may view these results as a positive indicator of the company’s growth potential and financial stability.
